This Article Full Text Full Text (PDF) All Versions of this Article: 38/5/1515    most recent 01.STR.0000263135.47779.9ev1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Saver, J. L. Search for Related Content PubMed PubMed Citation Articles by Saver, J. L. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Stroke Related Collections Neuroprotectors Acute Cerebral Infarction Acute Stroke Syndromes Emergency treatment of Stroke

(Stroke. 2007;38:1515.)
© 2007 American Heart Association, Inc.

Original Contributions

Clinical Impact of NXY-059 Demonstrated in the SAINT I Trial

Derivation of Number Needed to Treat for Benefit Over Entire Range of Functional Disability

From the Stroke Center and Department of Neurology, David Geffen School of Medicine at the University of California, Los Angeles.

Correspondence to Jeffrey L. Saver, MD, University of California, Los Angeles (UCLA) Stroke Center, 710 Westwood Plaza, Los Angeles, CA 90095. E-mail jsaver{at}ucla.edu

Background and Purpose— The SAINT I trial demonstrated that the neuroprotective agent NXY-059 improves the distribution of acute stroke patient outcomes on the modified Rankin Scale (mRS) of global disability. Standard dichotomized number-needed-to-treat (NNT) analyses for the magnitude of treatment benefit range widely, from 22.7 to infinity, and each capture only a portion of the observed beneficial shift in outcomes. Derivation of an NNT value reflecting the treatment’s benefit over the entire range of the mRS is required to describe the clinical import of the trial results.

Methods— The minimum and maximum possible NNTs for benefit over the range of mRS global disability outcomes were calculated by completing a joint distribution outcome table for a model population of 1000 patients, shifting responders by the greatest and smallest possible increments, respectively. The biologically most plausible NNT within this range was derived by having 10 neurologist and emergency-physician acute stroke-care experts independently specify the joint distribution of outcomes in model samples of 1000 patients assigned to placebo and active therapy.

Results— The minimum possible NNT for benefit incorporating all mRS state transitions is 7.9 and the maximum is 16.7. The biologically most plausible NNT for 1 additional patient to have a better outcome by 1 or more grades on the mRS outcomes is 9.8 (95% CI, 8.7 to 10.9).

Conclusions— Considering improvements in global disability over the entire outcome range, the SAINT I trial results indicate that for every 100 patients treated, 10 will benefit and none be harmed as a result of treatment.

Key Words: acute stroke • cerebrovascular disease • clinical trials • neuroprotective agents • stroke • therapy

This article has been cited by other articles:

				J. L. Saver Novel End Point Analytic Techniques and Interpreting Shifts Across the Entire Range of Outcome Scales in Acute Stroke Trials Stroke, November 1, 2007; 38(11): 3055 - 3062. [Abstract] [Full Text] [PDF]